Hepatitis C infection and risk of malignant lymphoma

Schöllkopf, Claudia; Smedby, Karin E.; Hjalgrim, Henrik; Rostgaard, Klaus; Panum, Inge; Vinner, Lasse; Chang, Ellen T.; Glimelius, Bengt; Porwit, Anna; Sundström, Christer; Hansen, Mads; Adami, Hans‐Olov; Melbye, Mads

doi:10.1002/ijc.23416

Cited by 70 publications

(54 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data including in the analysis seven previous surveys, demonstrating that HCV was associated with marginal zone lymphoma, diffuse large B-cell lymphoma, and lymphoplasmacytic lymphoma [4]. The association between HCV and lymphomas has been demonstrated also from population with a low prevalence of HCV [5]. The causal role of HCV in lymphomagenesis is also supported by the regression of indolent non-Hodgkin's lymphomas after eradicating the infection [6,7].…”

Section: Introductionmentioning

confidence: 90%

Impact of treatment‐related liver toxicity on the outcome of HCV‐positive non‐Hodgkin's lymphomas

et al. 2009

View full text Add to dashboard Cite

We studied 160 Hepatitis C virus (HCV)-positive patients with NHL (59 indolent NHL, 101 aggressive). Median age was 67 years. HCV-RNA was present in 146. HBsAg was positive in seven patients. At diagnosis, ALT value was above UNL in 67 patients. One hundred and twenty patients received an anthracycline-based therapy, alkylators, 28 received chemotherapy plus rituximab. Cytotoxic drugs dose was reduced in 63 patients. Among 93 patients with normal ALT at presentation, 16 patients developed WHO grade II-III liver toxicity. Among 67 patients with abnormal ALT, eight patients had a 3.5 times elevation during treatment. Among 28 patients treated with rituximab and chemotherapy, five patients (18%) developed liver toxicity. Thirty four patients (21%) did not complete treatment (eight for liver toxicity). Median progression-free survival (PFS) for patients who experienced liver toxicity is significantly shorter than median PFS of patients without toxicity (respectively, 2 years and 3.7 years, P 5 0.03). After a median F-UP of 2 years, 32 patients died (three for hepatic failure). A significant proportion of patients with HCV1 NHL develop liver toxicity often leading to interruption of treatment. This could be a limit to the application of immunochemotherapy programs. HCV1 lymphomas represent a distinct clinical subset of NHL that deserves specific clinical approach to limit liver toxicity and ameliorate survival. Am. J. Hematol. 85:46-50, 2010. V

show abstract

Section: Introductionmentioning

confidence: 90%

Impact of treatment‐related liver toxicity on the outcome of HCV‐positive non‐Hodgkin's lymphomas

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In contrast to a possible association between HCV infection and the risk of nonHodgkin's lymphoma, no HL patient was HCV-positive [77].…”

Section: Hepatitis C Virusmentioning

confidence: 82%

Liver Involvement in Hodgkin's Lymphoma: Types of Injuries and Therapeutic Implications

Mihăilă

2017

IJPPE

View full text Add to dashboard Cite

Abstract. The hepatocytolysis raises questions on following therapeutic conduct when it occurs during chemotherapy for Hodgkin's lymphoma, expression of its liver toxicity. But the onset of primary liver Hodgkin's lymphoma, including the form manifested by acute liver failure, poses even greater problems, as in the case of occurrence of vanishing bile duct syndrome -expression of a paraneoplastic syndrome, hemophagocytic lymphohistiocytosis, peliosis hepatis or association of lymphoma with infection with hepatitis viruses or human immunodeficiency virus or different autoimmune diseases. This review summarizes the clinical experience acquired on the relationship between Hodgkin's lymphoma and liver, from the point of view of clinical manifestations, used treatments and clinical evolution. Suggestions on the course of treatment in patients with Hodgkin's lymphoma and liver damage have been formulated starting from the metabolism and elimination of chemotherapy drugs and taking into account the clinical experience of published clinical trials and cases. This review is a synthesis of knowledge obtained in this field, during the time, of therapeutic possibilities and limits, and formulates potential future milestones for research.

show abstract

“…[2][3][4][5]9 Also, there are only two case reports in the literature that evaluate the effect of chemotherapy for Hodgkin's lymphoma on concurrent HCV infection. 5,9 In the first report, Vento et al 5 described a patient receiving ABVD chemotherapy for Hodgkin's disease.…”

Section: Discussionmentioning

confidence: 99%

“…1,2 However, an association of HCV with Hodgkin's lymphoma is not clear. [2][3][4] As many chemotherapeutic agents are hepatotoxic, treatment of HCV-positive lymphoma patients is a challenge. However, a major issue that has to be considered is the effect of commonly used chemotherapeutics, i.e.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C Virus Related Liver Dysfunction During Chemotherapy for Hodgkin’s Lymphoma

Erol¹

2012

UHOD

View full text Add to dashboard Cite

Concurrent Hodgkin's lymphoma and Hepatitis C virus (HCV) infection is a rare clinical condition. Also, HCV related liver dysfunction during lymphoma chemotherapy is uncommon and most data come from patients with non-Hodgkin's lymphoma. We reported here a case of HCV related liver dysfunction during chemotherapy for Hodgkin's lymphoma and long term follow-up results of the patient, and we reviewed the literature.Keywords: Hepatitis C, Infection, Liver dysfunction, Lymphoma ÖZET Hodgkin Lenfoma Kemoterapisi S›ras›nda Ortaya Ç›kan Hepatit C Virusu ile ‹liflkili Karaci¤er DisfonksiyonuHodgkin lenfoma ve Hepatitis C virus (HCV) infeksiyonu birlikteli¤i nadir bir klinik durumdur. Ayr›ca, lenfoma kemoterapisi esnas›nda ortaya ç›kan HCV reaktivasyonu da s›k karfl›lafl›lmayan bir durum olup, bu konudaki verilerin ço¤u da non-Hodgkin lenfomal› hastalardan gelmektedir. Biz burada Hodgkin lenfoma kemoterapisi s›ras›nda ortaya ç›kan HCV'ye ba¤l› bir karaci¤er disfonksiyonu olgusunu, bu olgunun uzun süreli sonuçlar›n› sunduk ve bu konudaki literatürü irdeledik

show abstract

Hepatitis C infection and risk of malignant lymphoma

Cited by 70 publications

References 52 publications

Impact of treatment‐related liver toxicity on the outcome of HCV‐positive non‐Hodgkin's lymphomas

Impact of treatment‐related liver toxicity on the outcome of HCV‐positive non‐Hodgkin's lymphomas

Liver Involvement in Hodgkin's Lymphoma: Types of Injuries and Therapeutic Implications

Hepatitis C Virus Related Liver Dysfunction During Chemotherapy for Hodgkin’s Lymphoma

Contact Info

Product

Resources

About